Gemini Therapeutics
Cambridge
About Gemini Therapeutics
Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $139.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:GMTX
- Website: geminitherapeutics.com
- Phone: info@geminitherapeutics.com
Industries & Categories
Biopharma, Biotechnology, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/gemini-therapeutics-292 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.